Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)

Li, Xin; Liu, Minghui; Zhang, Hongbing; Liu, Hongyu

doi:10.1111/1759-7714.13303

Cited by 7 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the most important growth factors is VEGF. VEGF can bind to receptors VEGFR-1 and VEGFR-2 on the surface of vascular endothelial cells, induce receptor dimerization, and phosphorylate the receptors' intracellular tyrosine kinase structure domain activation, activate PLC-g/PKC, RAS/MAPK and PI3K/AKT signaling pathways, induce endothelial cell proliferation, migration and cell survival (48)(49)(50)(51), and ultimately lead to tumor angiogenesis (52). At the same time, VEGF is also known to play a key role in the early stages of metastases (53)(54)(55).…”

Section: Combined Application Of Egfr-tki and Anti-vascular Endotheli...mentioning

confidence: 99%

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Peng

Yao²,

Pan³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) represented by gefitinib and erlotinib are widely used in treating non-small cell lung cancer (NSCLC). However, acquired resistance to EGFR-TKI treatment remains a clinical challenge. In recent years, emerging research investigated in EGFR-TKI-based combination therapy regimens, and remarkable achievements have been reported. This article focuses on EGFR-TKI-based regimens, reviews the standard and novel application of EGFR targets, and summarizes the mechanisms of EGFR-TKI combinations including chemotherapy, anti-vascular endothelial growth factor monoclonal antibodies, and immunotherapy in the treatment of NSCLC. Additionally, we summarize clinical trials of EGFR-TKI-based combination therapy expanding indications to EGFR mutation-negative lung malignancies. Moreover, novel strategies are under research to explore new drugs with good biocompatibility. Nanoparticles encapsulating non-coding RNA and chemotherapy of new dosage forms drawn great attention and showed promising prospects in effective delivery and stable release. Overall, as the development of resistance to EGFR-TKIs treatment is inevitable in most of the cases, further research is needed to clarify the underlying mechanism of the resistance, and to evaluate and establish EGFR-TKI combination therapies to diversify the treatment landscape for NSCLC.

show abstract

Section: Combined Application Of Egfr-tki and Anti-vascular Endotheli...mentioning

confidence: 99%

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Peng

Yao²,

Pan³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Soluble cytokines have been reported to prevent viral replication by inducing the expression of many interferon-stimulated genes, thereby activating antiviral and antiproliferative states [ 23 ]. It has been reported that the binding of VEGFR can promote the growth of blood vessels in lung cancer [ 24 ], thereby affecting tumor proliferation. In addition, VEGFR was recently found to be highly expressed during inflammation [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Exploration of the Potential Link, Hub Genes, and Potential Drugs for Coronavirus Disease 2019 and Lung Cancer Based on Bioinformatics Analysis

Wang

Zhang³

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

The ongoing pandemic of coronavirus disease 2019 (COVID-19) has a huge influence on global public health and the economy. Lung cancer is one of the high-risk factors of COVID-19, but the molecular mechanism of lung cancer and COVID-19 is still unclear, and further research is needed. Therefore, we used the transcriptome information of the public database and adopted bioinformatics methods to identify the common pathways and molecular biomarkers of lung cancer and COVID-19 to further understand the connection between them. The two RNA-seq data sets in this study—GSE147507 (COVID-19) and GSE33532 (lung cancer)—were both derived from the Gene Expression Omnibus (GEO) database and identified differentially expressed genes (DEGs) for lung cancer and COVID-19 patients. We conducted Gene Ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis and found some common features between lung cancer and COVID-19. We also performed TFs-gene, miRNAs-gene, and gene-drug analyses. In total, 32 DEGs were found. A protein-protein interaction (PPI) network was constructed by DEGs, and 10 hub genes were screened. Finally, the identified drugs may be helpful for COVID-19 treatment.

show abstract

“…In case 7, reported by Iezumi et al (10), CSCLC patients received a combined chemotherapy regimen of cisplatin and irinotecan hydrochloride and received radiotherapy for metastasis and recurrence in the forearm. For CSCLC patients with EGFR mutations, use currently mature epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and other drug-related molecular targeted therapies to exert anti-tumor activity (17,18). Some researchers believe that pure SCLC and CSCLC have similar clinical manifestations and that the operation outcomes of both in a limited stage are similar.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Combined Small Cell Lung Carcinoma With Pulmonary Adenocarcinoma

Shen

Che

2022

Front. Surg.

View full text Add to dashboard Cite

BackgroundCombined small cell lung carcinoma is defined as cancer tissues that mainly contain small cell lung cancer (SCLC) components with non-SCLC (NSCLC) histopathological types. The most common part of NSCLC is squamous cell carcinoma or large cell carcinoma. Combined SCLC (CSCLC) contains adenocarcinoma is extremely rare.Case PresentationWe reported a case with surgically treated diagnosed as CSCLC with adenocarcinoma in an elderly and we summarized the clinical features of this disease. The patient has remained well for over 2 weeks after the treatment.ConclusionThere are still few research reports on CSCLC. Since the survival time of patients with advanced CSCLC is shorter than that of simple SCLC, the recommended treatment for CSCLC is early detection and early surgery. In order to facilitate preoperative diagnosis and avoid misdiagnosis of such rare diseases, more cases need to be reported.

show abstract

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)

Cited by 7 publications

References 13 publications

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Exploration of the Potential Link, Hub Genes, and Potential Drugs for Coronavirus Disease 2019 and Lung Cancer Based on Bioinformatics Analysis

Case Report: Combined Small Cell Lung Carcinoma With Pulmonary Adenocarcinoma

Contact Info

Product

Resources

About